



Inify
Laboratories

Inify Laboratories

Year-end report for the fourth quarter and full year 2025

This is Inify Laboratories



Who we are

Inify Laboratories is based in Sweden and its shares are listed on Euronext Growth Oslo. The company has two subsidiaries; Inify Laboratories Nordics AB and Inify Laboratories Ltd.



How we do it

Inify has built a unique and ultramodern laboratory and developed a fully digital, standardized and AI-assisted workflow in order to optimize quality and shorten response times. The diagnostic services is offered for selected cancer types, where specialization contributes to high and reliable quality.



What we do

Inify Laboratories provides cancer diagnostics in histopathology. Our laboratory offers diagnostic services to both public and private healthcare providers. The business model and technical structure allow for scalability in volume, diagnosis and geographical expansion.



Why we do it

Clinical pathology is currently under great pressure, with high workloads and limited – even declining – resources. An aging population, increasing cancer incidence, and more frequent examinations and screening programmes further increase the workload. Solving the problem through labor alone is not an option, it is necessary to work in new ways.

Our vision:
**World leading cancer
diagnostics for everyone!**

Fourth quarter highlights

- Net sales 6.3 MSEK (4.8)
- Gastrointestinal patient-samples diagnosed
- Share issue of NOK 100 million initiated

Full year 2025 highlights

- Net sales of 22.2 MSEK (13.7)
- Expansion to new diagnostic area
- Ongoing establishment in the UK

Key figures	Q4 2025	Q4 2024		Full year 2025	Full year 2024
Average number of shares	78,903,416	45,236,750		62,070,083	45,236,750
Earnings per share (SEK)	-0.26	-0.31		-0.86	-1.14
Solidity	76.4%	77.9%		76.4%	77.9%
Sales (TSEK)	6,455	4,839		22,228	13,706
EBITDA (TSEK)	-19,850	-13,142		-64,797	-48,362
Cash at period end	57,532	22,684		57,532	22,684

The company use some figures that are considered as Alternative Performance Measures. Please see description under section Alternative Performance Measures and Definitions.



Letter from the CEO

Continued growth, access to UK laboratory and positive response to gastrointestinal diagnostics

In the fourth quarter, sales grew by 33% compared to the same period last year. Inify Laboratories Nordics continued to deliver positive results, both for the quarter and for the full year. Cash balance at the end of the period amounted to SEK 57.5 million.

Establishment in the UK

We are making significant progress towards completing the laboratory in Milton Park. In December, we gained access to the laboratory area of the premises and received our instrumentation, allowing installation of most of the equipment to begin. We expect to complete installations immediately after the turn of the year, and then to begin testing and verification of the entire system. The application for the necessary permits to conduct routine medical activities has been submitted to the relevant authorities.

We have deepened our dialogue with customers within the public healthcare NHS, at both national and regional levels.

Initially, this includes funded pilot projects for the evaluation of our services. We are making steady progress while navigating a complex structure that involves many decision-makers. During the quarter, representatives from several prominent NHS hospitals visited our laboratory in Sweden, which we see as a clear sign of growing interest. Our initial offering will include diagnostics in prostate cancer, where most customer dialogues are already well advanced. Following the establishment of gastrointestinal diagnostics in Sweden, we will gradually introduce this diagnostic area into our UK operations as well. Our diagnostic system is designed for smooth implementation across all our laboratory operations.

“Since the opening of our Swedish laboratory in June 2023, over five thousand patient cases have been diagnosed”

“For each patient diagnosed by Inify, structured and standardised data is generated, enabling us to produce high-quality research data – through just a few clicks.”

Gastrointestinal diagnostics

In September, our gastrointestinal diagnostics services were launched in Sweden, and the first patient samples were successfully diagnosed. As expected, additional samples at start-up scale have been diagnosed, which is of great importance in optimising the process in this diagnostic area. Customer feedback has been unequivocally positive and has provided valuable input for further development.

We are addressing a market with very large sample volumes and enormous capacity needs. Hundreds of thousands of endoscopy examinations are performed annually in Sweden alone, many of which result in tissue sampling. Month-long waiting times are not uncommon, creating a clear opportunity to make a meaningful difference through guaranteed response times of a couple of weeks.

Going forward, the diagnostic burden is expected to increase further, driven in part by screening programmes. Market activities aimed at potential customers in Sweden are ongoing, and we anticipate that both sample volumes and sales in this diagnostics area will grow gradually over time.

Sales development

We continued to see strong sales growth compared to the corresponding period last year – clear acknowledgement of the tangible added value we deliver. Revenue primarily comes from prostate cancer diagnostics. Since the opening of our Swedish laboratory in June 2023, over five thousand patient cases have been diagnosed – all delivered within five working days from sample collection at the clinic, fully in line with our customer promise.

A steady inflow of gastrointestinal samples contributed a smaller share of revenues in the fourth quarter, with a gradual increase expected going forward.

Furthermore, we have ongoing dialogues with several regions. The number of stakeholders, combined with strict procurement requirements, adds complexity and results in longer processes. It is still a matter of perseverance, but we are making real progress and are optimistic about our further growth in Sweden.

Financing

We initiated a new share issue of NOK 100 million, once again fully guaranteed by our two largest shareholders. The offer was directed exclusively to existing shareholders. In December, a subscription agreement was signed for the first part – a directed share issue to the six largest shareholders. Five of them chose to participate in the issue, which we see as a strong vote of confidence in the company's future development.

Agreements for participants in the subsequent repair issue were signed after the turn of the year. Full payment for the issue is planned for March 2026. The capital injection secures financial stability in the ongoing investment phase in the UK as well as resilience in longer, time-consuming sales processes, particularly within public healthcare. We are both grateful and humbled by the strong, long-term confidence shown by our guarantors and other shareholders.

Unique data for research and development

Three abstracts based on our data were presented in collaboration with customers at the annual Swedish National Urology Meeting in October, and were received with great interest. The abstracts provide insights into diagnostic coherence between different pathologists, important choices in sampling, and correlation between radiological risk assessment and pathological diagnosis in different age groups.

In addition, an abstract has been accepted for presentation at the upcoming European Urology Conference (EAU), to be held in London in March. The abstract is based on data from routine clinical diagnostics and supports the suggestion to review guidelines for the number of samples taken per lesion for targeted biopsy procedures. These insights have the potential to further advance and improve the conditions for high-quality diagnostics in the future.

We are seeing a growing number of requests to participate in or contribute to various research projects. This is partly driven by an increasing volume of routine prostate cancer diagnostics in Sweden, but even more so by our optimised process with structured data.

For each patient diagnosed by Inify, structured and standardised data is generated, enabling us to produce high-quality research data – with unparalleled time efficiency and data quality – through just a few clicks. Sharing data and collaborating with various healthcare stakeholders to advance cancer research is fully in line with our vision.

Organisation

During the fourth quarter, we expanded our UK team with additional administrative and laboratory staff. They have undergone training in Sweden and are now well prepared to take on great responsibility in the completion and commissioning of our UK laboratory.

Outlook

We close an eventful year with another quarter of strong growth and a further fully guaranteed financing, providing continued financial stability and endurance. Significant progress in development, sustained growth, and deepened dialogue with existing and potential customers across our markets give me great confidence as we look ahead.

Fredrik Palm
Chief Executive Officer

Fourth quarter and full year 2025

Company history and development

Inify Laboratories AB (publ) is a Swedish company with its registered office in Stockholm, Sweden, and operates as the parent company of the Inify Laboratories group. The company was incorporated in November 2021 as a subsidiary to Context-Vision AB. Following a resolution at an extraordinary general meeting, Inify Laboratories was spun-off in February 2022 through a dividend of shares. Shortly thereafter, the company's shares were listed on Euronext Growth, Oslo.

In January 2023, a wholly owned, Swedish subsidiary was formed to support the business structure with a suitable organization. The laboratory launched its pathology services for healthcare providers in mid June 2023.

At the end of 2024, another wholly-owned subsidiary was established, based in the UK where the establishment of the business began in 2025.

The Group provides clinical diagnostic services for prostate cancer and gastro-intestinal diagnostics.

Inify Laboratories Group

The Group consists of the parent company Inify Laboratories AB (publ), with company registration number 559345-4431, the wholly owned subsidiary Inify Laboratories Nordics AB with company registration number 559416-6828, and the wholly-owned, UK subsidiary Inify Laboratories Ltd with company number 15997568.

Inify Laboratories AB

The Parent Company's business consists of research and development, management of intangible assets, Group Management and other administrative services at Group level. The company has its own development department that further develops systems and methods and conducts research in areas such as gastrointestinal diagnostics.

Inify Laboratories Nordics AB

The Swedish subsidiary was formed in January 2023 and its operations mainly consist of running the day-to-day laboratory and diagnostics operations in the Group's first laboratory in Solna. The company also contributes to the Group's research projects and development work.

Inify Laboratories Ltd

The subsidiary in the UK was formed in October 2024 and did not operate in 2024. During 2025, the subsidiary has established a local laboratory for the operation of laboratory and diagnostics operations with the goal of being ready to receive

patient samples in the beginning of 2026.

Financial development

During the fourth quarter of 2025, the Group's operating income amounted to SEK 6,455 thousand (4,839) and for the full year to SEK 22,228 thousand (13,706), which corresponds to an increase compared to the same quarter previous year of 33% (472%) and to 62% (101%) for the full year. The increase in sales is related to the gradually increasing number of customers and the fact that larger volumes of patient samples have been diagnosed during the period. The broadening to the gastrointestinal diagnostics business contributed with a smaller number of samples and some smaller revenues in the fourth quarter. All operating income relates to diagnostic services within Sweden and has been made in SEK.

Other external costs amounted to SEK 10.7 million (7.3) in the fourth quarter and SEK 35.6 million (24.6) for the full year. The increase compared to the corresponding periods last year is mainly attributable to the new subsidiary in the UK and the establishment of the new laboratory. Start-up costs and investments related to the establishment in the UK are expected to continue also in the beginning of 2026.

Personnel costs for the fourth quarter amounted to SEK 13.9 million (10.1) and for the full year to SEK 47.1 million (35.6). The increase in personnel costs compared with the corresponding periods last year is a natural consequence of the fact that the organization has grown and more employees have been hired. New hires have been made on an ongoing basis in all Group companies, both Swedish and foreign.

Operating results

The group's consolidated operating result in the fourth quarter of 2025 was SEK -21.0 million (-14.3) and for the full year SEK -69.7 million (-53.0). Results after financial items was SEK -20.7 million (-14.2) in the fourth quarter and SEK -67.9 million (-51.6) for the full year. EBITDA for the quarter was SEK -19.9 million (-13.1) and for the full year -64.8 (-48.4).

Cash flow and financing

As of December 31, 2025, liquid assets for the Group amounted to SEK 57.5 million (22.7). Cash flow for the fourth quarter amounted to SEK -54.6 million (-12.1) and for the full year 2025 to SEK 34.8 million (-48.2). During the quarter, major investments were made in the UK subsidiary, which explains the increased negative cash flow. Equity at the end of the period amounted to SEK 107.4 million (33.4), resulting in an equity ratio of 76.4% (77.9%).

In December 2024, a new share issue of approximately SEK 150 million was initiated, which was completed in February 2025 when the share issue amount was paid to the company. The raised capital is mainly being used for financing the expansion into the UK, further development of the system for additional diagnoses and as working capital for the existing operations.

In December 2025, another new share issue of approximately NOK 100 million was initiated, which is expected to be completed in March 2026 when the issue amount is expected to be paid.

Tangible and intangible assets

For intangible assets a depreciation period of 5 years is applied. For tangible assets a depreciation period of 5 years is also applied, with the exception of construction investments, which in the UK are depreciated over a period of 10 years.

Tangible assets at the end of the period amounted to SEK 67.4 million (8.1). The large increase in tangible assets is mainly attributable to investments in premises and machinery and equipment for the newly built British laboratory.

The intangible assets consist of the product Inify Prostate™, a decision support tool for prostate cancer diagnostics. It was originally developed by ContextVision, and was acquired and further developed by Inify Laboratories. It now serves as a fully integrated component of the in-house developed laboratory information system. Intangible assets at the end of the period amounted to SEK 2.2 million (4.2).

Inventories

Inventories are valued at the lower of cost and net realisable value. The cost of inventories is calculated by applying the principle of the first in, first out method (FIFO). Inventories at the end of the period amounted to SEK 1.7 million (0.9). The increase in inventory value is mainly attributable to purchases for the new laboratory in the UK.

Leasing

Inify leases the combined office and laboratory facility on Campus Solna, which houses both the first laboratory and the Group's head office. The company also leases office space in Linköping, primarily intended for R&D activities. In addition, there are some smaller leasing commitments for vehicles, office equipment and laboratory equipment.

A new lease agreement for a newly built facility in Milton Park outside Oxford was signed in May, where the business in the UK will be established. A deposit of SEK 2.8 million was paid to the landlord in connection to the signing of the agreement.

Employees

On December 31, 2025, the Group had a total of 37 (26) employees, whereof 31 (26) located in Sweden and 6 (0) in UK. Of these, 23 (20) were employees of the parent company, 8 (6) of the Swedish subsidiary and 6 (0) of the UK subsidiary.

Incentive program

The Company's general meeting resolved on 9 May 2022 to implement a long-term incentive program for employees (the "Employee Incentive Program") and a long-term incentive program for board members (the "Board Member Incentive Program"). The long-term incentive program consists of a maximum of 3,935,599 options, divided between the Employee Incentive Program and the Board Member Incentive Program. Assuming that all options are exercised, this will correspond to a total dilution of approximately 8% based on the number of outstanding shares at the date of this report. Each option entitles the holder to acquire a new share or a warrant entitling to one share in the Company at an exercise price of NOK 4.80. The granted options vests over a 36-month period and may, as a general rule, only be exercised for the acquisition of new shares if the participant is still employed and the other conditions for qualified employee stock options under the Income Tax Act are met. The holder of options may exercise granted and vested options during the period from the end of the vesting period up to and including the tenth year from the date of grant.

Transactions which are eliminated by consolidation

Intra-group receivables and liabilities, income or expenses, and unrealised gains or losses arising from intra-group transactions between Group companies, are eliminated in the preparation of the consolidated financial statements. As of the balance sheet date of 31 December 2025, the parent company had group receivables totalling SEK 63.1 million (5.7) relating to the both subsidiaries.

Related party transactions

Transactions between the parent company and its subsidiary arise naturally in the operations as, for example, premises and certain resources are shared between the companies. The group transactions for the quarter have mainly concerned the invoicing of rents and services shared between the companies. During the fourth quarter, total intra-group revenues in the parent company amounted to SEK 805 thousand (664) and in the Swedish subsidiary to SEK 1,060 thousand (0). For the full year the intra-group revenues in the parent company amounted to SEK 2,947 thousand (2,435) and in the Swedish subsidiary to SEK 1,060 thousand (0). A group contribution of SEK 5,160

thousand from the Swedish subsidiary to the parent company was recorded in December 2025.

Extraordinary General Meeting and new share issue

At an Extraordinary General Meeting on 6 December 2025, the EGM resolved on the issuance of 28,571,429 new shares through a guaranteed share issue with a total value of approximately NOK 100 million. The issue is made in two parts, where the first part, corresponding to approximately NOK 92 million, was directed to the largest shareholders and where the subscription period ended on December 16, 2025. The second part of the issue is directed to other shareholders and corresponds to approximately NOK 8 million. The subscription period for the second tranche ended on 26 January 2026. The payment date for both parts of the issue is 26 March 2026 and the newly issued shares are expected to be delivered on or about 30 March 2026.

Risks and uncertainties

The main risk factors and uncertainties for the Group include, but are not limited to, risks related to the business and industry in which the Company operates, legal and regulatory risks, risks related to the Company's financial situation and risks relating to the shares and the listing of the shares on Euronext Growth Oslo. In addition to above, the management closely monitors and regularly evaluates any risk that may arise as a result of inflation, increasing energy prices or international instability. For further details on the company's main risk factors, please refer to the Information Document published in connection with the listing on Euronext Growth in June 2022, to the Annual Report for 2024 published on April 16, 2025 and to the national prospectus published on 7 January 2025. The risks and uncertainties associated with existing operations are not expected to have changed significantly since then.

Basis of preparation

The condensed financial statements for the third quarter 2025, ending December 31, 2025 have been prepared in accordance with the Annual Accounts Act and the Swedish Accounting Board's general advice BFNAR 2012:1 Annual accounts and consolidated accounts ("K3"). The condensed financial statements do not include all the information and disclosures required in the annual financial statements. For detailed information, see the company's annual report for 2024, which can be found on the website

The functional and reporting currency of the group is Swedish kronor (SEK). All amounts, unless otherwise stated, are presented in SEK thousand.

New and changed accounting principles

No new or changed accounting principles have had effect on the accounting for the period.

Subsequent events

The subscription period for the new share issue that began in December 2025 closed in January 2026. The issue of the shares and payment of the newly subscribed shares is expected to take place in March 2026. See further information under the section "Extraordinary General Meeting and new share issue" above.

In addition to above, no other significant events have occurred during the period from the balance sheet date and the issuance of this report.

Proposed dividend

The Board of Directors does not propose an ordinary dividend for the full year 2025.

Shareholder information

- Inify Laboratories ABs shares were listed on Euronext Growth Oslo on June 20, 2022 under the ticker INIFY (ISIN SE0017486103).
- As of December 31, 2025, the Company had a total of 78,903,416 outstanding shares. All shares have equal rights and are freely transferable.
- As of December 31, 2025, Inify had a total of 991 shareholders, of which 3 held more than 10% each of the shares.
- Detailed information about major shareholders can be found on the company's website www.inify.com.
- The 10 largest shareholders as of December 31, 2025 are listed in the table below.

	No of shares	%	Shareholder
1	47,410,660	60.09	Gallivant S.á.r.l.
2	9,236,652	11.71	Tauri AS
3	8,043,896	10.19	Monsun AS
4	2,610,770	3.31	BRAS Kapital
5	1,964,768	2.49	Günther-Hanssen, Sven
6	1,889,770	2.40	Danske Bank A/S
7	1,382,243	1.75	MP PENSJON PK
8	829,297	1.05	Avanza Bank AB
9	539,300	0.68	OLSEN, LARS EJNAR
10	425,800	0.54	STAVLAND, PER
11	4,574,491	5.80	Others
	78,903,416	100	Total

Financial calendar

This interim report was published on the company's website on the 25 of February 2026. For further information, please visit www.inify.com.

25 February 2026	Publication of Q4 and full year 2025 Financial report
15 April 2026	Publication of Annual Report 2025
29 April 2026	Publication of Q1 2026 Financial report
20 May 2026	Annual General Meeting
26 August 2026	Publication of Q2 2026 Financial report
28 October 2026	Publication of Q3 2026 Financial report
24 February 2027	Publication of Q4 and full year 2026 Financial report

Key figures

	Q4 2025	Q4 2024	Full year 2025	Full year 2024
Number of shares at period end	78 903 416	45 236 750	78 903 416	45 236 750
Average number of shares	78 903 416	45 236 750	62 070 083	45 236 750
Earnings per share	-0.26	-0.31	-0.86	-1.14
Solidity (percent)	76.4%	77.9%	76.4%	77.9%
EBITDA	-19 850	-13 142	-64 797	-48 362

The company use some figures that are considered as Alternative Performance Measures.
Please see description under section Alternative Performance Measures and Definitions.

Consolidated income statement in summary SEK 1000

	Q4 2025	Q4 2024	Full year 2025	Full year 2024
Net sales	6 340	4 488	22 006	13 131
Other income	115	351	222	575
Total operating income	6 455	4 839	22 228	13 706
Cost of goods	-993	-572	-3 403	-1 880
Other external costs	-10 684	-7 295	-35 643	-24 557
Other operating expenses	-730	-17	-877	-78
Personnel costs	-13 898	-10 097	-47 102	-35 552
Depreciation	-1 146	-1 173	-4 860	-4 624
Operating results	-20 996	-14 315	-69 657	-52 986
Interest income	385	69	1 850	1 484
Interest cost	-74	-1	-79	-140
Results after financial items	-20 685	-14 247	-67 886	-51 643
Tax	0	0	0	0
Net results	-20 685	-14 247	-67 886	-51 643

Consolidated statement of comprehensive income SEK 1000

	Q4 2025	Q4 2024	Full year 2025	Full year 2024
Net result for the period	-20 685	-14 247	-67 886	-51 643
Other comprehensive income				
Other comprehensive income that may be reclassified to profit or loss in subsequent periods (net of tax)	0	0	0	0
Translation difference	0	0	0	0
Total comprehensive income	-20 685	-14 247	-67 886	-51 643

Consolidated balance sheet in summary SEK 1000

			December 31, 2025	December 31, 2024
Assets				
Intangible fixed assets			2 186	4 205
Tangible assets			67 399	8 137
Other financial assets			2 684	875
Inventories and other current assets			1 717	914
Current receivables			9 034	6 088
Cash and bank			57 532	22 684
Total assets			140 552	42 902
Equity and liabilities				
Equity			107 439	33 403
Other provisions			2 841	0
Current liabilities			30 272	9 499
Total equity and liabilities			140 552	42 902

Consolidated change in equity in summary SEK 1000

	Q4 2025	Q4 2024	Full year 2025	Full year 2024
Opening balance	127 629	47 650	33 403	85 046
Total comprehensive income for the period	-20 685	-14 247	-67 886	-51 643
Translation difference	495	0	320	0
Share issue	0	0	141 602	0
Total	107 439	33 403	107 439	33 403

Parent company income statement in summary SEK 1000

	Q4 2025	Q4 2024	Full year 2025	Full year 2024
Net sales	806	664	2 947	2 435
Other income	115	121	222	345
Total operating income	920	786	3 169	2 780
Other external costs	-7 903	-6 811	-29 831	-22 673
Other operating expenses	-730	-17	-877	-71
Personnell costs	-9 354	-8 412	-34 227	-29 943
Depreciation	-1 153	-1 153	-4 612	-4 561
Operating results	-18 220	-15 608	-66 378	-54 468
Interest income	374	51	1 791	1 427
Interest cost	0	0	-5	-128
Results after financial items	-17 846	-15 557	-64 592	-53 168
Group contribution	5 160	0	5 160	0
Results after group contribution	-12 686	-15 557	-59 432	-53 168
Tax	0	0	0	0
Net results	-12 686	-15 557	-59 432	-53 168

Parent company balance sheet in summary SEK 1000

	December 31, 2025	December 31, 2024
Assets		
Intangible fixed assets	2 186	4 205
Tangible assets	5 230	7 824
Other financial assets	244	1 117
Current receivables	67 978	9 579
Cash and bank	48 578	17 711
Total assets	124 216	40 435
Equity and liabilities		
Equity	114 048	31 878
Current liabilities	10 168	8 557
Total equity and liabilities	124 216	40 435

Parent company change in equity in summary SEK 1000

	Q4 2025	Q4 2024		Full year 2025	Full year 2024
Opening balance	126 734	47 435		31 878	85 046
Total comprehensive income for the period	-12 686	-15 557		-59 432	-53 168
Share issue	0	0		141 602	0
Total	114 048	31 878		114 048	31 878

Signatures

The board and the CEO certify that this interim report for the period 1 October – 31 December 2025 to the best of our knowledge, includes a fair and true review of the company's significant events, operations, financial position, results and related party transactions, and also describes the significant risks and uncertainties that the company faces. This report has not been reviewed by the company's auditors.

Stockholm, 24 February, 2026

Olof Sandén
Chairman of the board

Fredrik Palm
CEO

Martin Ingvar
Boardmember

Magne Jordanger
Boardmember

Alternative performance measures and definitions

In its financial reports, the company presents certain financial measures, including Key Figures, which are considered as Alternative Performance Measures (APM). The company believes that these figures provide useful supplementary information to investors and the company's board and management as they enable a better evaluation of the company's financial performance. Because not all companies calculate the financial figures in the same way, these are not always comparable to measures used by other companies.

Key figure	Definition	Motivation for usage
Earnings per share after tax (Return on equity)	Net result for the period divided by the number of outstanding shares at period end.	Earnings per share shows the company's results in relation to shares, and provides additional information regarding the company's profitability.
Solidity (Equity ratio)	Equity at period end as a percentage of total assets.	The equity ratio shows the company's long term ability to pay its debts and is a complement to other key figures. It helps assess the possibility of dividends.
EBITDA	Earnings before interest, taxes, depreciation and amortization. Operating profit/loss before interest, taxes, impairment and depreciation/amortization.	EBITDA shows the company's underlying development, which is valuable as an indication of the company's underlying cash-generating capacity.

Definitions

Accreditation

Accreditation is a formal recognition that an organization is competent to perform specified tasks in testing, inspection and certification.

Artificial Intelligence (AI)

Artificial Intelligence is the intelligence exhibited by machines or software.

Biopsy

A small tissue sample.

Digital Pathology

Digital pathology refers to the digital images of histopathology samples. The digitalization is achieved by scanning the prepared samples.

Endoscopy

The use of a flexible tube with a camera, known as an endoscope, to inspect the inside of different organs. An endoscope that is used to investigate the stomach is called a gastroscope and an endoscope for examination of the colon is called a colonoscope.

Gastroenterology

An examination of the gastro-intestinal tract with an endoscope. Using the endoscope it is possible to take tissue samples and remove pre-cancerous lesions.

GI

Gastro-intestinal.

Histopathology

Examination of tissue specimens to study the visible manifestations of disease.

Image analysis

Processing a digital image in order to describe/classify its contents or to extract quantitative measurements.

LIS

Laboratory Information System

Machine Learning

Machine learning is the study of computer algorithms that automatically improve through experience.

MDT

Multidisciplinary Team Meeting is a meeting of professionals from one or more [clinical](#) disciplines who together make decisions regarding recommended treatment of individual patients.

NHS

National Health Service.

Pathology report

A medical report provided to the referring physician that describes the characteristics of a piece of tissue, blood, or body organ that has been removed from the body.

Referral/request

Order from a physician for a diagnostic examination of a specimen of tissue or other samples from a patient.

Specimen

Part of a human body (e.g., Biopsy Specimen) or organ that is to be examined by the laboratory.



Inify
Laboratories

© 2025 Inify Laboratories

Inify Laboratories offers diagnostics through specialised laboratory services in histopathology, with a focus on streamlining patient pathways. The company performs clinical diagnostics in prostate cancer and gastroenterology, providing an integrated service that spans from early sample handling to final diagnosis. The laboratory system is scalable both in handling large volumes of patient samples and for replicating in new locations. Inify Laboratories is an international group headquartered in Stockholm, Sweden, with local laboratories in Sweden and the UK. The company's share is listed on Euronext Growth Oslo under the ticker INIFY.